Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Fabrus
La Jolla, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Prior to acquisition, Fabrus reported generation of next-generation antibodies able to successfully target difficult cell surface receptors and ion channels for oncology (including renal cell carcinoma) and inflammation. No disclosed completed clinical trial results; programs were either preclinical or approaching IND[1][2][4].
- Therapeutic areas
- OncologyImmunology
- Modalities
- Monoclonal antibodyAntibodyBiologic
- Industry
- Biotech
02
Partnerships
Pfizer (pharma/biotech antibody discovery partnership)Opko Health (investor and board representation)
Beyond the preview
Go deeper on Fabrus.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fabrus.